

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
If you wonder why Congress critters keep ignoring what the people want them to do -- while doing things that people don't want them doing -- take a peek at the unique PR campaign now being run by the pharmaceutical industry.
The public is dismayed and disgusted by the flagrant greed of drugmakers that are shamefully zooming the prices of medicines into the stratosphere, turning necessities into unaffordable luxuries. As a result, there's a growing demand for Congress to take action to stop the industry's out-of-control price gouging.
To counter this, drug companies have launched a massive advertising campaign. They're running ads on radio, in print, and on Facebook and Twitter painting themselves as the good guys.
Yet you probably haven't seen or heard any of them. That's because drug chieftains don't care what you and I think. Moreover, they know they couldn't possibly persuade us to let them keep jacking up their prices.
Instead, their "public" relations effort has made the odd and seemingly counterproductive move of sidestepping the actual public to narrowly target a very tiny audience.
As Celgene executive Bob Hugin arrogantly put it: "We've identified 7,000 Americans who matter." The other 330 million of us, apparently, are nobodies.
"We're focusing on those in policy positions," Hugin sniffed, "to fight structural issues." By that, he means convincing Congress not to reform the present pricing structure of monopolistic drugmakers, whose guiding corporate ethic is "bleed 'em for all they've got."
So this is a surreptitious PR campaign meant to reach only the eyes and ears of policy elites. The goal is to have Congress -- once again -- ignore what the people want it to do, thus allowing the corporate few "who matter" to keep fleecing the rest of us.
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
If you wonder why Congress critters keep ignoring what the people want them to do -- while doing things that people don't want them doing -- take a peek at the unique PR campaign now being run by the pharmaceutical industry.
The public is dismayed and disgusted by the flagrant greed of drugmakers that are shamefully zooming the prices of medicines into the stratosphere, turning necessities into unaffordable luxuries. As a result, there's a growing demand for Congress to take action to stop the industry's out-of-control price gouging.
To counter this, drug companies have launched a massive advertising campaign. They're running ads on radio, in print, and on Facebook and Twitter painting themselves as the good guys.
Yet you probably haven't seen or heard any of them. That's because drug chieftains don't care what you and I think. Moreover, they know they couldn't possibly persuade us to let them keep jacking up their prices.
Instead, their "public" relations effort has made the odd and seemingly counterproductive move of sidestepping the actual public to narrowly target a very tiny audience.
As Celgene executive Bob Hugin arrogantly put it: "We've identified 7,000 Americans who matter." The other 330 million of us, apparently, are nobodies.
"We're focusing on those in policy positions," Hugin sniffed, "to fight structural issues." By that, he means convincing Congress not to reform the present pricing structure of monopolistic drugmakers, whose guiding corporate ethic is "bleed 'em for all they've got."
So this is a surreptitious PR campaign meant to reach only the eyes and ears of policy elites. The goal is to have Congress -- once again -- ignore what the people want it to do, thus allowing the corporate few "who matter" to keep fleecing the rest of us.
If you wonder why Congress critters keep ignoring what the people want them to do -- while doing things that people don't want them doing -- take a peek at the unique PR campaign now being run by the pharmaceutical industry.
The public is dismayed and disgusted by the flagrant greed of drugmakers that are shamefully zooming the prices of medicines into the stratosphere, turning necessities into unaffordable luxuries. As a result, there's a growing demand for Congress to take action to stop the industry's out-of-control price gouging.
To counter this, drug companies have launched a massive advertising campaign. They're running ads on radio, in print, and on Facebook and Twitter painting themselves as the good guys.
Yet you probably haven't seen or heard any of them. That's because drug chieftains don't care what you and I think. Moreover, they know they couldn't possibly persuade us to let them keep jacking up their prices.
Instead, their "public" relations effort has made the odd and seemingly counterproductive move of sidestepping the actual public to narrowly target a very tiny audience.
As Celgene executive Bob Hugin arrogantly put it: "We've identified 7,000 Americans who matter." The other 330 million of us, apparently, are nobodies.
"We're focusing on those in policy positions," Hugin sniffed, "to fight structural issues." By that, he means convincing Congress not to reform the present pricing structure of monopolistic drugmakers, whose guiding corporate ethic is "bleed 'em for all they've got."
So this is a surreptitious PR campaign meant to reach only the eyes and ears of policy elites. The goal is to have Congress -- once again -- ignore what the people want it to do, thus allowing the corporate few "who matter" to keep fleecing the rest of us.